Swiss pharma manufacturing remains steady despite tariff threats, impact may take years

Swiss biotech day event highlighted that pharma manufacturing in Switzerland shows no immediate disruption from geopolitical tensions or potential tariffs.

Industry representatives said that while current operations continue unchanged, any shift of production to the United States could take several years to materialize and affect supply chains.

Analysts note that the longer-term impact remains uncertain, but for now Swiss facilities appear resilient and investors see no immediate risk.